Christian Karsten Hansen

From Wikipedia, the free encyclopedia
Jump to: navigation, search

Christian Karsten Hansen, PhD, MBA (born 18 August 1966) is a Danish biotechnology entrepreneur, investor and inventor, with work in new drugs, molecular biology and biochemistry.

Personal background[edit]

Originally from Copenhagen, Denmark, he spent his childhood in Antwerpen, Belgium and Caracas, Venezuela before completing high school at Sorø Academy in 1984. Following graduation as M.Sc. chemical engineering from the Technical University of Denmark in 1989,[1] PhD work in molecular biology and biochemistry was conducted at the Pasteur Institute,[2][3][4] France and the University of Salamanca,[5] Spain. He also completed an MBA from the Edinburgh Business School, Scotland.[6]

Professional background[edit]

Hansen held positions as senior scientist and director of intellectual property management at Novo Nordisk 1992–1999, and was a member of Enzyme Research Management.[6] He co-founded one of the early Danish biotechnology companies, Profound Pharma,[7][8] in 1999, with Jan Møller Mikkelsen,[9] and remained co-CEO thereof until its acquisition by Maxygen in 2000.[10] In 2001, he co-founded the investment firm Nordic Biotech Advisors,[1][11] subsequently renamed NB Capital.[12][13][14][15][16][17] Also in 2001, he founded C Hansen Invest.

Since 2001, Hansen has co-founded or been a board member of numerous privately held and listed biotechnology companies including Osteologix,[18][19] Nuevolution,[15][20] Curalogic,[6] Forward Pharma,[21] Rose Pharma,[22] Poalis,[15] Aditech Pharma, Veloxis Pharmaceuticals,[23] H Pharmaceuticals, and Isar Pharma.[24]

Patents[edit]

Hansen has filed numerous patent applications in the fields of genetics of bacteria, cellulases and other enzymes, osteoporosis, and protein engineering and uses of biopharmaceuticals. He is named as inventor of issued European patents 510091,[25] 1250154,[26] 1425304,[27] 1534305,[28] 1622629,[29] 1622630,[30] 1732575,[31] 1745791[32] 2266584[33] and 2266585,[34] and US patents 5,843,720,[35] 5,916,796,[36] 6,066,473,[37] 6,555,660,[38] 6,646,110,[39] 6,831,158,[40] 7,230,081,[41] 7,232,562,[42] 7,504,237,[43] 7,550,565,[44] 7,550,566,[45] 7,595,342,[46] 7,696,153[47] and 8,541,471.[48]

Various compounds from these patents are in mid and late stages of clinical development, including new strontium salts for osteoporosis.[49][50][51][52]

References[edit]

  1. ^ a b "Festglad venturekapitalist – Diverse". Business.dk. Retrieved 10 November 2011. 
  2. ^ http://jb.asm.org/cgi/reprint/174/11/3522.pdf
  3. ^ "Gene : In vivo genetic engineering: homologous recombination as a tool for plasmid construction". ScienceDirect. Retrieved 10 November 2011. 
  4. ^ "Gene : Multiple endo-β-1,4-glucanase-encoding genes from Bacillus lactus PL236 and characterization of the celB gene". ScienceDirect. Retrieved 10 November 2011. 
  5. ^ "FEBS Letters : Fibronectin type III-like sequences and a new domain type in prokaryotic depolymerases with insoluble substrates". ScienceDirect. Retrieved 10 November 2011. 
  6. ^ a b c http://www.euroinvestor.dk/pdf/cse/140531-0.pdf
  7. ^ "Rose Pharma – Board". Gastrotechpharma.com. Retrieved 10 November 2011. 
  8. ^ "Speed, aggression, surprise!". Mva.org. Retrieved 10 November 2011. 
  9. ^ "Dansk bioteks Lance Armstrong – Navne". Business.dk. Retrieved 10 November 2011. 
  10. ^ "Maxygen Reports 2000 Third quarter Financial Results. – Free Online Library". Thefreelibrary.com. Retrieved 10 November 2011. 
  11. ^ http://www.mva.org/media(1947,1033)/Medicon_Valley_Patent_Guide.pdf
  12. ^ "NB Capital". NB Capital. Retrieved 10 November 2011. 
  13. ^ "Vækstfonden – Portefølje". Vf.dk. Retrieved 10 November 2011. 
  14. ^ "European Biotechnology News :: Nordic biotech gets Euro41.5m fund". Eurobiotechnews.eu. Retrieved 10 November 2011. 
  15. ^ a b c "Danish venture capital company Nordic Biotech raises second biotech venture fund (in English)". Mva.org. Retrieved 10 November 2011. 
  16. ^ http://venturebeatprofiles.com/person/profile/christian-hansen
  17. ^ Christian Hansen PhD. "NB Capital ApS: Private Company Information – BusinessWeek". Investing.businessweek.com. Retrieved 10 November 2011. 
  18. ^ "2005 Archives". Osteologix. 29 November 2004. Retrieved 10 November 2011. 
  19. ^ http://www.osteologix.com/media/10q_2009_q2.pdf
  20. ^ "Biotech companies in Medicon Valley popular among investors – Invest in Denmark". Investindk.com. 30 October 2007. Retrieved 10 November 2011. 
  21. ^ "Christian Hanse". Forward-pharma.com. Retrieved 10 November 2011. 
  22. ^ http://www.rosepharma.com
  23. ^ http://www.mva.org/media(1946,1033)/Financing_Guide_2004.pdf
  24. ^ "Isar Pharma K/S: News Release". Marketwire.com. Retrieved 10 November 2011. 
  25. ^ http://worldwide.espacenet.com/publicationDetails/biblio?CC=EP&NR=0510091&KC=&locale=en_EP&FT=E
  26. ^ "espacenet – Bibliographic data". V3.espacenet.com. 23 October 2002. Retrieved 10 November 2011. 
  27. ^ "espacenet – Bibliographic data". V3.espacenet.com. 9 June 2004. Retrieved 10 November 2011. 
  28. ^ "espacenet – Original document". V3.espacenet.com. Retrieved 10 November 2011. 
  29. ^ http://worldwide.espacenet.com/publicationDetails/biblio?CC=EP&NR=1622629&KC=&locale=en_EP&FT=E
  30. ^ http://worldwide.espacenet.com/publicationDetails/biblio?CC=EP&NR=1622630&KC=&locale=en_EP&FT=E
  31. ^ "espacenet – Bibliographic data". V3.espacenet.com. 20 December 2006. Retrieved 10 November 2011. 
  32. ^ http://worldwide.espacenet.com/publicationDetails/biblio?CC=EP&NR=1745791&KC=&locale=en_EP&FT=E
  33. ^ http://worldwide.espacenet.com/publicationDetails/biblio?CC=EP&NR=2266584&KC=&locale=en_EP&FT=E
  34. ^ http://worldwide.espacenet.com/publicationDetails/biblio?CC=EP&NR=2266585&KC=&locale=en_EP&FT=E
  35. ^ "Introduction of DNA into bacillus strains by conjugation – US Patent 5843720 Description". Patentstorm.us. Retrieved 10 November 2011. 
  36. ^ "Enzyme exhibiting cellulase activity – US Patent 5916796 Full Text". Patentstorm.us. Retrieved 10 November 2011. 
  37. ^ "Introduction of DNA into bacillus strains by conjugation – US Patent 6066473 Description". Patentstorm.us. Retrieved 10 November 2011. 
  38. ^ "G-CSF conjugates – US Patent 6555660 Full Text". Patentstorm.us. Retrieved 10 November 2011. 
  39. ^ "G-CSF polypeptides and conjugates – US Patent 6646110 Full Text". Patentstorm.us. Retrieved 10 November 2011. 
  40. ^ "G-CSF conjugates – US Patent 6831158 Full Text". Patentstorm.us. Retrieved 10 November 2011. 
  41. ^ "Interferon gamma conjugates – US Patent 7230081 Full Text". Patentstorm.us. Retrieved 10 November 2011. 
  42. ^ "E38N interferon gamma polypeptide variants – US Patent 7232562 Full Text". Patentstorm.us. Retrieved 10 November 2011. 
  43. ^ "Polynucleotides encoding interferon gamma polypeptides – US Patent 7504237 Full Text". Patentstorm.us. Retrieved 10 November 2011. 
  44. ^ "G-CSF conjugates – US Patent 7550565 Full Text". Patentstorm.us. Retrieved 10 November 2011. 
  45. ^ "G-CSF conjugates – US Patent 7550566 Full Text". Patentstorm.us. Retrieved 10 November 2011. 
  46. ^ "Water-soluble strontium salts for use in treatment of cartilage and/or bone conditions – US Patent 7595342 Full Text". Patentstorm.us. Retrieved 10 November 2011. 
  47. ^ "G-CSF conjugates – US Patent 7696153 Full Text". Patentstorm.us. Retrieved 10 November 2011. 
  48. ^ http://www.patentstorm.us/patents/8541471/fulltext.html
  49. ^ "News". Osteologix. 30 March 2009. Retrieved 10 November 2011. 
  50. ^ "A Dose-response Study With Strontium Malonate in Postmenopausal Women – Full Text View". ClinicalTrials.gov. Retrieved 10 November 2011. 
  51. ^ "Treatment of Neutropenia, G-CSF, Neutrophils, Chemotherapy, Protein Therapeutics, Pegylated, Clinical Trial, Neupogen, Neulasta, Blood, Bone Marrow, Breast cancer, Lung cancer, Lymphomas, Leukemias". Maxygen.com. Retrieved 10 November 2011. 
  52. ^ "Evaluation of Maxy-G34 in Breast Cancer Patients Treated With TAC (Docetaxel, Adriamycin, Cyclophosphamide) Chemotherapy – Full Text View". ClinicalTrials.gov. Retrieved 10 November 2011.